Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aimei Health Technology (AFJK) Shares Outstanding (Diluted Average) (2023 - 2025)

Aimei Health Technology (AFJK) has 3 years of Shares Outstanding (Diluted Average) data on record, last reported at $4.0 million in Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 87.95% to $4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 87.95% increase, with the full-year FY2024 number at $6.9 million, up 892.0% from a year prior.
  • Shares Outstanding (Diluted Average) reached $4.0 million in Q3 2025 per AFJK's latest filing, roughly flat from $4.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for AFJK hit a ceiling of $6.9 million in Q4 2024 and a floor of $695565.0 in Q4 2023.
  • A 3-year average of $3.4 million and a median of $3.1 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 892.0% in 2024, then skyrocketed 87.95% in 2025.
  • Tracing AFJK's Shares Outstanding (Diluted Average) over 3 years: stood at $695565.0 in 2023, then skyrocketed by 892.0% to $6.9 million in 2024, then plummeted by 42.09% to $4.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for AFJK at $4.0 million in Q3 2025, $4.0 million in Q2 2025, and $5.2 million in Q1 2025.